Please login to the form below

Not currently logged in
Email:
Password:

UCLA MRSA antibiotic study wins USD 9m from NIH

The US National Institute of Allergy and Infectious Diseases, which is part of the US National Institutes of Health has awarded a UCLA research team a five-year, USD 9m contract to fund a study investigating antibiotic treatments for community acquired MRSA (methicillin-resistant Staphylococcus aureus).

The US National Institute of Allergy and Infectious Diseases (NIAID), which is part of the US National Institutes of Health (NIH), has awarded a UCLA research team a five-year, USD 9m contract to fund a study investigating antibiotic treatments for community acquired MRSA (methicillin-resistant Staphylococcus aureus).

The study will be headed up by Dr David A Talan and Dr Gregory J Moran of Olive View-UCLA Medical Center and the David Geffen School of Medicine at UCLA.

The research will examine if off-patent antibiotics for the treatment of uncomplicated skin and soft tissue infections could treat MRSA.

Dr Talan said: "The emergence of the new, potentially more infectious and virulent strain of S. aureus in the community, has caused serious outbreaks of disease over the past few years. We are hopeful to be able to identify the most effective antibiotic treatment for these infections."

The current team published a study in the New England Journal of Medicine (NEJM) that CA-MRSA had become the most common cause of skin and soft tissue infections among patients presenting to a geographically diverse group of 11 emergency departments across the US.

MRSA resistance to antibiotics was measured in-vitro and found that in 57 per cent of cases, doctors had prescribed an antibiotic to which the bacteria were resistant.

Despite the findings, in-vitro testing does not reliably indicate that these antibiotics would fail in patients with an active immune system to help fight disease. More research, including the study supported by the NIH award, will address the impact of MRSA resistance to various off-patent antibiotics.

The researchers say that this NIH contract is unique, as it will fund the investigation of off-patent antibiotics which would not normally be tested by pharmaceutical industry-supported research.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Genetic Digital

Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....